Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2073-2079

  Bodelon, C ^a   Polley, M Y ^a   Kemp, T J ^b   Pesatori, A C ^c   McShane, L M ^a   Caporaso, N E ^a   Hildesheim, A ^a   Pinto, L A ^b   Landi, M T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

CCL15; Inflammatory markers; Lung cancer; Survival

Indexed keywords

CHEMOKINE; CHEMOKINE CCL15; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; HUMAN; LONG TERM SURVIVAL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT TERM SURVIVAL; SMOKING; SURVIVAL TIME;

CCL15; INFLAMMATORY MARKERS; LUNG CANCER; SURVIVAL;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84881255344     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt175     Document Type: Article

References (36)

1. The Top Ten Causes of Death. In Center WM (ed), Fact sheet. World Health Organization, 2008.
2. Jemal A, Siegel R, Xu J et al. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Saynak M, Hubbs J, Nam J et al. Variability in defining T1N0 non-small cell lung cancer impacts locoregional failure and survival. Ann Thorac Surg 2010; 90: 1645-1649; discussion 1649. -1650.
4. Kelsey CR, Marks LB, Hollis D et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 2009; 115: 5218-5227.
5. Fujimoto T, Cassivi SD, Yang P et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg 2006; 132: 499-506.
6. Rodriguez LA, Wallander MA, Martin-Merino E et al. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med 2010; 104: 1691-1699.
7. Loomis D, Dement JM, Wolf SH et al. Lung cancer mortality and fibre exposures among North Carolina asbestos textile workers. Occup Environ Med 2009; 66: 535-542.
8. Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med 1955; 12: 81-86.
9. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer 2004; 44: 287-293.
10. Parsons A, Daley A, Begh R et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340: b5569.
11. Sardari Nia P, Weyler J, Colpaert C et al. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 2005; 47: 351-359.
12. Walser T, Cui X, Yanagawa J et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc 2008; 5: 811-815.
13. Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009; 9: 375-383.
14. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13: 118-137.
15. Pine SR, Mechanic LE, Ambs S et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007; 99: 1401-1409.
16. Shaw AD, Vaporciyan AA, Wu X et al. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. Ann Thorac Surg 2005; 79: 1704-1710.
17. Lin M, Stewart DJ, Spitz MR et al. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 2011; 32: 1050-1056.
18. Wu X, Ye Y, Rosell R et al. Genome-wide association study of survival in nonsmall cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011; 103: 817-825.
19. Ma H, Shu Y, Pan S et al. Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer 2011; 74: 164-169.
20. Seike M, Yanaihara N, Bowman ED et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007; 99: 1257-1269.
21. Brattstrom D, Bergqvist M, Hesselius P et al Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002; 37: 57-63.
22. Joensuu H, Anttonen A, Eriksson M et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002; 62: 5210-5217.
23. Enewold L, Mechanic LE, Bowman ED et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009; 18: 215-222.
24. White ES, Flaherty KR, Carskadon S et al Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003; 9: 853-860.
25. Chaturvedi AK, Kemp TJ, Pfeiffer RM et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1902-1911.
26. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
27. Landi MT, Consonni D, Rotunno M et al Environment and Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer. BMC Public Health 2008; 8: 203.
28. Travis WD, Brambilla E, Harris CC et al. World Health Organization Classification of Tumours, Pathology and Genetics: tumors of the lung, pleura, thymus and heart. Lyon, France: IARC Press, 2004.
29. AJCC Cancer Staging Manual. New York: Springer-Verlag, 2010.
30. Travis WD, Brambilla E, Noguchi M et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
31. Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B (Stat Methodol) 2002; 64: 479-498.
32. Wang W, Bacon KB, Oldham ER et al. Molecular cloning and functional characterization of human MIP-1 delta, a new C-C chemokine related to mouse CCF-18 and C10. J Clin Immunol 1998; 18: 214-222.
33. Ko J, Kim IS, Jang S-W et al Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells. FEBS Lett 2002; 515: 159-164.
34. Pardigol A, Forssmann U, Zucht HD et al. HCC-2, a human chemokine: gene structure, expression pattern, and biological activity. Proc Natl Acad Sci USA 1998; 95: 6308-6313.
35. Joubert P, Lajoie-Kadoch S, Wellemans V et al. Expression and regulation of CCL15 by human airway smooth muscle cells. Clin Exp Allergy 2012; 42: 85-94.
36. Hwang J, Kim CW, Son KN et al. Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett 2004; 570: 47-51.